Compare FRPT & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRPT | CORT |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 9.7B |
| IPO Year | 2014 | 2001 |
| Metric | FRPT | CORT |
|---|---|---|
| Price | $73.04 | $114.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 5 |
| Target Price | $76.94 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.87 | N/A |
| EPS | ★ 1.29 | 0.09 |
| Revenue | ★ $1,102,015,000.00 | $761,407,000.00 |
| Revenue This Year | $11.34 | $26.08 |
| Revenue Next Year | $9.13 | $26.98 |
| P/E Ratio | ★ $56.38 | $1,228.89 |
| Revenue Growth | ★ 13.01 | 12.79 |
| 52 Week Low | $46.45 | $28.66 |
| 52 Week High | $86.00 | $122.21 |
| Indicator | FRPT | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 71.50 | 64.64 |
| Support Level | $64.96 | $76.41 |
| Resistance Level | $86.00 | $122.21 |
| Average True Range (ATR) | 3.25 | 5.13 |
| MACD | 1.00 | -0.09 |
| Stochastic Oscillator | 94.90 | 75.23 |
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (likely representing well north of 90% of sales), with cats and treats nascent contributors. Geographically, the company's home US market, where all its food is produced, accounts for nearly all of sales, with exports to Canada, the United Kingdom, and other European countries being very small contributors.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.